ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome (Q57764209)

13

0 references

author name string

L. De Luca

1

0 references

L. Bolognese

2

0 references

M. Valgimigli

3

0 references

R. Ceravolo

4

0 references

G. B. Danzi

5

0 references

E. Piccaluga

6

0 references

S. Rakar

7

0 references

A. Cremonesi

8

0 references

F. M. Bovenzi

9

0 references

R. Abbate

10

0 references

F. Andreotti

11

0 references

L. Bolognese

12

0 references

F. M. Bovenzi

14

0 references

R. Caporale

16

0 references

P. Capranzano

17

0 references

N. Carrabba

18

0 references

G. Casella

19

0 references

C. Cavallini

20

0 references

R. Ceravolo

21

0 references

P. Colombo

22

0 references

M. R. Conte

23

0 references

S. Cordone

24

0 references

A. Cremonesi

25

0 references

G. B. Danzi

26

0 references

M. Del Pinto

27

0 references

G. De Luca

28

0 references

L. De Luca

29

0 references

S. De Servi

30

0 references

E. Di Lorenzo

31

0 references

G. Di Pasquale

32

0 references

G. Esposito

33

0 references

R. Farina

34

0 references

A. Fiscella

35

0 references

D. Formigli

36

0 references

S. Galli

37

0 references

P. Giudice

38

0 references

G. Gonzi

39

0 references

C. Greco

40

0 references

N. B. Grieco

41

0 references

L. La Vecchia

42

0 references

M. Lazzari

43

0 references

C. Lettieri

44

0 references

M. Lettino

45

0 references

U. Limbruno

46

0 references

A. Lupi

47

0 references

A. Macchi

48

0 references

M. Marini

49

0 references

M. Marzilli

50

0 references

A. Montinaro

51

0 references

G. Musumeci

52

0 references

A. Navazio

53

0 references

Z. Olivari

54

0 references

L. Oltrona Visconti

55

0 references

J. A. Oreglia

56

0 references

F. Ottani

57

0 references

G. Parodi

58

0 references

G. Pasquetto

59

0 references

G. Patti

60

0 references

A. Perkan

61

0 references

G. P. Perna

62

0 references

E. Piccaluga

63

0 references

F. Piscione

64

0 references

F. Prati

65

0 references

S. Rakar

66

0 references

R. Ravasio

67

0 references

F. Ronco

68

0 references

R. Rossini

69

0 references

A. Rubboli

70

0 references

F. Saia

71

0 references

G. Sardella

72

0 references

G. Satullo

73

0 references

S. Savonitto

74

0 references

P. Sbarzaglia

75

0 references

G. Scorcu

76

0 references

N. Signore

77

0 references

G. Tarantini

78

0 references

P. Terrosu

79

0 references

L. Testa

80

0 references

M. Tubaro

81

0 references

S. Valente

82

0 references

M. Valgimigli

83

0 references

F. Varbella

84

0 references

M. Vatrano

European Heart Journal Supplements

85

0 references

publication date

28 November 2014

0 references

published in

0 references

volume

16

0 references

page(s)

C2-C28

0 references

issue

suppl C

0 references

cites work

Antithrombotic therapy in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Medical Management After Coronary Stent Implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticlopidine and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Early and late effects of clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Current antiplatelet therapies: benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Bioequivalence in the real world is a complex challenge: the case of clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticagrelor--is there need for a new player in the antiplatelet-therapy field?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (T

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Disparities in management patterns and outcomes of patients with non-ST-elevation acute coronary syndrome with and without a history of cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Triple antiplatelet therapy in acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Early versus delayed, provisional eptifibatide in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Composition of coronary thrombus in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Facilitated PCI in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Regis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Combining antiplatelet and anticoagulant therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intraveno

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clinical epidemiology, management and outcome of acute coronary syndromes in the Italian network on acute coronary syndromes (IN-ACS Outcome study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of ANTithRombotic Agents: the MANTRA registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Renal function and outcomes in acute coronary syndrome: impact of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Diabetes and antiplatelet therapy in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Current concepts on coronary revascularization in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Bedside evaluation of thienopyridine antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Emergence of the concept of platelet reactivity monitoring of response to thienopyridines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Antithrombotic therapy in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Percutaneous coronary intervention pharmacology: from a triangle to a square.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Anemia and mortality in acute coronary syndromes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Treatment options for patients with poor clopidogrel response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clopidogrel use and bleeding after coronary artery bypass graft surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Impact of preoperative clopidogrel in off pump coronary artery bypass surgery: a propensity score analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Clopidogrel treatment before coronary artery bypass graft surgery increases postoperative morbidity and blood product requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Bridging therapy after recent stent implantation: case report and review of data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Antiplatelet drugs: mechanisms and risks of bleeding following cardiac operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FSUU030